View in EDS

ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicator for Neoadjuvant Therapy.

Saved in:
Bibliographic Details
Title: ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicator for Neoadjuvant Therapy.
Authors: Omiya K; Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Oba A; Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. atsushi.oba@jfcr.or.jp.; Department of Hepatobiliary and Pancreatic Surgery, Institute of Science Tokyo, Tokyo, Japan. atsushi.oba@jfcr.or.jp.; Division of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. atsushi.oba@jfcr.or.jp., Sugiura K; Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Maekawa A; Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.; Department of Hepatobiliary and Pancreatic Surgery, Institute of Science Tokyo, Tokyo, Japan., Mie T; Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Kobayashi K; Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Ono Y; Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Ito H; Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Inoue Y; Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Takahashi Y; Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. yu.takahashi@jfcr.or.jp.
Source: Annals of surgical oncology [Ann Surg Oncol] 2025 Aug; Vol. 32 (8), pp. 5434-5435. Date of Electronic Publication: 2025 May 21.
Publication Type: Journal Article
Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 9420840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-4681 (Electronic) Linking ISSN: 10689265 NLM ISO Abbreviation: Ann Surg Oncol Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:1534-4681
DOI:10.1245/s10434-025-17458-8